文献速递流行病学与生物统计临床试验与 GCP

癌症随机临床试验中总生存期如何评估及后续治疗线是否被考虑:一项系统综述

How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review.
PubMed 文献 · Trials · 2023-11-06

该系统综述通过两次MEDLINE检索纳入134篇论文,其中98篇(73%)呈现临床试验结果,45篇(46%)将总生存期作为(共同)主要终点;59篇(60%)提及后续治疗,仅7篇进行额外分析,主要针对对照组患者在随访期间接受实验性治疗(治疗转换)的情况。

要点

  • 总生存期正从主要终点逐渐转为次要终点。
  • 多数论文提及后续治疗,但仅少数进行额外分析。
  • 作者指出在试验随访期间患者接受抗癌治疗时存在方法学空白。

核心结论

  • 总生存期已逐渐从主要终点转变为次要终点,但论文在呈现总生存期结果时仍会提及后续治疗这一限制因素,却很少或未研究其影响。
  • 本综述表明,对于试验参与者在随访期间接受抗癌治疗时研究者应如何处理,存在方法学空白。

研究设计与样本

  • 系统综述,于2021年11月9日在OVID©的MEDLINE中进行两次检索。
  • 第一次检索旨在识别八个知名期刊中发表随机对照试验总生存期结果的论文,第二次检索旨在识别提及或考虑后续治疗的论文。
  • 纳入2010年以来发表、在治疗癌症背景下呈现或讨论总生存期的论文,共纳入134篇论文。

主要发现

  • 134篇论文中多数呈现临床试验结果(98篇,73%)。
  • 呈现临床试验结果的论文中,45篇(46%)将总生存期报告为(共同)主要终点。
  • 与将总生存期作为次要终点的论文相比,将总生存期作为(共同)主要终点的论文在近年发表的比例较低。
  • 各论文对总生存期的主要分析方法不一。
  • 59篇(60%)提及后续治疗;7篇论文进行了额外分析,主要针对对照臂患者在试验随访期间接受实验性治疗(治疗转换)的情况。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overall survival is the "gold standard" endpoint in cancer clinical trials. It plays a key role in determining the clinical- and cost-effectiveness of a new intervention and whether it is recommended for use in standard of care. The assessment of overall survival usually requires trial participants to be followed up for a long period of time. In this time, they may stop receiving the trial intervention and receive subsequent anti-cancer treatments, which also aim to extend survival, during trial follow-up. This can potentially change the interpretation of overall survival in the context of the clinical trial. This review aimed to determine how overall survival has been assessed in cancer clinical trials and whether subsequent anti-cancer treatments are considered. METHODS: Two searches were conducted using MEDLINE within OVID© on the 9th of November 2021. The first sought to identify papers publishing overall survival results from randomised controlled trials in eight reputable journals and the second to identify papers mentioning or considering subsequent treatments. Papers published since 2010 were included if presenting or discussing overall survival in the context of treating cancer. RESULTS: One hundred and thirty-four papers were included. The majority of these were presenting clinical trial results (98, 73%). Of these, 45 (46%) reported overall survival as a (co-) primary endpoint. A lower proportion of papers including overall survival as a (co-) primary endpoint compared to a secondary endpoint were published in recent years. The primary analysis of overall survival varied across the papers. Fifty-nine (60%) mentioned subsequent treatments. Seven papers performed additional analysis, primarily when patients in the control arm received the experimental treatment during trial follow-up (treatment switching). DISCUSSION: Overall survival has steadily moved from being the primary to a secondary endpoint. However, it is still of interest with papers presenting overall survival results with the caveat of subsequent treatments, but little or no investigation into their effect. This review shows that there is a methodological gap for what researchers should do when trial participants receive anti-cancer treatment during trial follow-up. Future research will identify the stakeholder opinions, on how this methodological gap should be addressed.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Royle KL, Meads D, Visser-Rogers JK, et al. How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review. Trials. 2023. PMID: 37926806. doi:10.1186/s13063-023-07730-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。